알리고스 테라퓨틱스(ALGS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $6.89 (+1.77%), 시가총액 $0.04B, 52주 범위 $5.25 ~ $13.29.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collabor
알리고스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
알리고스 테라퓨틱스의 현재 주가는 $6.89 (+1.77%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
알리고스 테라퓨틱스의 시가총액은 약 $0.04B입니다.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate,